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AbstrACt 
Objectives To investigate the relative performance of 
hip prosthesis constructs as compared with the best 
performing prosthesis constructs and illustrate the 
substantial variability in performance of currently used 
prostheses.
Design A non-inferiority study.
setting The National Joint Registry for England, Wales, 
Northern Ireland and the Isle of Man (NJR).
Participants All patients with a primary total hip 
replacement registered in the NJR between 1 April 2003 
and 31 December 2016.
Main outcome measures Kaplan-Meier failure 
function for hip prosthesis constructs. Failure difference 
between best performing construct and remaining 
constructs.
Methods Using a non-inferiority analysis, the performance 
of hip prosthesis constructs by brand were compared with 
the best performing contemporary construct. Construct failure 
was estimated using the 1-Kaplan-Meier survival function 
method, that is, an estimate of net failure. The difference in 
failure between the contemporary benchmark and all other 
constructs was tested.
results Of the 4442 constructs used, only 134 had 
≥500 procedures at risk at 3 years postprimary, 89 
of which were not demonstrated to be inferior to the 
benchmark by at least 100% relative risk. By 10 years 
postprimary, there were 26 constructs with ≥500 at risk, 
13 of which were not demonstrated to be inferior by at 
least 20% relative risk. Even fewer constructs were not 
inferior to the benchmark when analysed by age and 
gender. At 5 years postprimary, there were 15 constructs 
in males and 11 in females, aged 55–75 years, not 
shown to be inferior.
Conclusions There is great variability in construct 
performance and the majority of constructs have not 
been demonstrated to be non-inferior to contemporary 
benchmarks. These results can help to inform patients, 
clinicians and commissioners when considering hip 
replacement surgery.
IntrODuCtIOn
When patients are considering a hip replace-
ment, they would be forgiven for thinking that 
all hip prostheses function equally.1 However, 
all prostheses are not equal as evidenced by 
the failure of the 3M Capital hip implant 
and metal-on-metal bearings.2 The extent to 
which patients and clinicians are aware of this 
lack of equality is unclear.
The National Joint Registry for England, 
Wales, Northern Ireland and the Isle of Man 
(NJR) was established to monitor the effec-
tiveness of different types of joint replace-
ment surgery, improve clinical standards and 
to identify poorly performing implants. It 
has not focused on identifying exceptionally 
well-performing implants due to limitations 
inherent with routine data collection and 
interpreting data from a standpoint of cause 
and effect. The NJR publishes the unadjusted 
strengths and limitations of this study
 ► Data collected from the largest joint registry in the 
world.
 ► For the first time, we have explicitly compared the 
performance of prosthesis constructs to a contem-
porary reference.
 ► Unambiguous presentation of data allows surgeons, 
patients and policy makers to directly compare 
commonly used prosthesis constructs to a reference 
construct.
 ► Residual and unmeasured confounding factors are 
likely to be present.
 ► The number of patients remaining at risk after ex-
tended follow-up is low, and therefore the power 
to detect non-inferiority after extended follow-up is 
also low.
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cumulative failure rates of the most commonly used stem 
and cup brand combinations used in hip replacement 
surgery.3
Therefore, the role of promoting perceived good prac-
tice has been filled by other organisations such as the 
Orthopaedic Device Evaluation Panel (ODEP) in the UK,4 
the Netherlands Orthopaedic Association in the Nether-
lands5 and the Australian superior clinical performance 
programme.6 Benchmarking bodies typically attempt to 
provide some type of classification to describe whether an 
implant is functioning at an acceptable level or not.
In the absence of evidence from randomised control 
trials, benchmarking organisations and prostheses 
registries are currently the best sources of evidence for 
prosthesis performance. However, both registries and 
benchmarking bodies have limitations which make the 
interpretation of prosthesis, or prosthesis construct, 
performance difficult. The cumulative failure reported by 
the NJR gives an indication of implant construct perfor-
mance in absolute terms, but head-to-head comparison of 
different constructs is difficult to estimate without more 
advanced statistical manipulation. The ODEP grading 
system is focused on individual implants rather than the 
constructs they form and is based on meeting an accept-
able externally decided benchmark. This simple dichot-
omisation does not facilitate comparison between the 
many different prosthesis constructs being used today 
or illustrate the extensive variability in so-called well-per-
forming prostheses.7
Sayers et al recently proposed a method of comparison 
for joint replacement prostheses using a non-inferiority 
design against an external benchmark.8 However, the 
primary limitation of this method is the arbitrary require-
ment for an externally specified benchmark.
In a non-inferiority clinical trial9 that has failure as an 
outcome, two treatments (comparator and reference) 
can be directly compared  to ensure that the comparator 
treatment is within a clinically acceptable range (non-in-
feriority margin) of performance at a specified point in 
time.10 11 Therefore, standard methods for conducting 
non-inferiority trials could be applied in an orthopaedic 
benchmarking setting, assuming an appropriate compar-
ator, non-inferiority margin and time of interest can be 
identified. This is a method we have applied in a medical 
device setting, namely knee replacements using NJR 
data, in which we assessed the non-inferiority of knee 
replacement constructs as compared with a benchmark 
construct.12
Choosing an appropriate contemporary reference is 
difficult. There is no evidence from randomised trials that 
suggests any prosthesis construct outperforms all others, 
therefore the choice of reference is more heuristic. 
Patients would like to receive the best available care and 
clinicians would like to provide the best possible care, or 
at least care that is non-inferior to the best. Therefore, 
the natural choice of reference against which all other 
prostheses should be compared is the construct with the 
lowest failure rate. However, in order to protect against 
chance, good fortune and a low observed failure rate, the 
construct should be used in large enough numbers to 
mitigate sampling variability.
As the failure rate of prostheses is known to be influ-
enced by both age and gender, the choice of reference 
should reflect this specificity,13 whereas the selection of 
an appropriate time and non-inferiority margin to assess 
prosthesis performance is much more subjective, as is the 
reader’s specific interest. For example, a surgeon inter-
ested in an older patient with lower life expectancy may 
be interested in minimising short-term complications 
opposed to ensuring long-term implant survivorship.
The aim of this study is to investigate the relative 
performance of hip prosthesis constructs as compared 
with the best performing prosthesis constructs using a 
non-inferiority study design, and illustrate the substantial 
variability in performance of currently used prostheses. 
Stem, bearing and cup brand combinations (constructs) 
are examined against non-inferiority margins of 20% 
relative risk and 100% relative risk at 3, 5, 7 and 10 years 
following surgery.
MethODs
Patients and data sources
We identified all patients with a primary total hip replace-
ment (THR) registered in the NJR between 1 April 2003 
and 31 December 2016. All patients were consented to be 
included in the NJR as part of the standard NJR process.
Procedures were included if the bearing surface was 
either metal-on-polyethylene (MoP), ceramic-on-poly-
ethylene (CoP) or ceramic-on-ceramic (CoC). Proce-
dures using any other bearing surfaces were excluded 
as were hemiarthroplasty procedures. Procedures were 
also excluded if the patient age and gender were missing, 
or the National Health Service number was untraceable 
and therefore mortality unknown. Metal-on-metal pros-
thesis constructs were excluded as their very high failure 
rates across all ages and both genders have already been 
demonstrated2 14 and their use no longer reflects contem-
porary practice.7
Patient and public involvement
Patient representatives sit on the committee structure of 
the National Joint Registry. The research priorities of the 
National Joint Registry are identified by this committee 
structure and approved by the patient representatives. 
Patients were not involved in the setting of the research 
question or the outcome measures, nor were they involved 
in designing or implementing this work or interpretation 
of the results. We are unable to disseminate results of this 
study directly to study participants due to the anonymous 
nature of the data. We plan to disseminate our findings 
to the National Joint Registry, via their communications 
team, to relevant to the provision of joint replacement 
and to the general population through the local and 
national press.
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Primary exposure
The primary exposure used in this analysis is hip pros-
thesis construct. This is defined by the femoral stem, 
acetabular cup combination and bearing combination. 
Groupings were defined using data recorded by the NJR 
and based on the catalogue numbers of individual hip 
prosthesis.
statistical methods
Using a non-inferiority analysis, the performance of hip 
prosthesis constructs was compared with an internally 
identified reference group. Prosthesis construct failure 
was estimated using the 1-Kaplan-Meier method, that is, 
an estimate of net failure.
Failure is defined using the first linked surgical revi-
sion; patients were censored at death or administratively 
censored on 31 December 2016. In a recent national 
audit of NJR procedure recording compliance,15 the 
percentage capture rates were 95.7% and 90.3% for 
primary and revision procedures, respectively. The differ-
ence in stratum-specific failure probabilities compared 
with the reference were calculated at 3, 5, 7 and 10 years 
for all prosthesis (stem–cup) combinations, stratified 
by gender and stratified by gender and age group (<55, 
55–75 and >75 years).
The difference and 95% CI of the difference between 
the comparator prosthesis construct and the reference 
prosthesis construct was estimated at the specified time 
points. The SE of the difference was constructed using a 
pooled estimate of the Greenwood SE,16
 
⌢
SE(Diff) =
√
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2
ref  
 and a z-test comparing the 
difference between the reference and test prosthesis was 
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Z =
((⌢
Fxi −
⌢
Fref
)
+ δ
)
/
⌢
SE
(
Diff
)
.
 
 
The stratum-specific contemporaneous reference 
construct was selected as the stem–cup and bearing 
combination with the lowest failure rate with at least 1000 
patients at risk at the time point of interest. The choice 
of 1000 procedures of the same construct was based 
on simulation work by Sayers et al which demonstrated 
that 1000 procedures at risk will give rise to a CI width 
of ~3% (±1.5%).8 We believe this represents an accept-
able minimal level of accuracy to be considered a suitable 
reference standard.
Two non-inferiority margins were chosen to illustrate 
the sensitivity of the choice. The first margin was conser-
vatively set at a 20% increase in relative risk of failure 
compared with the reference, in line with clinical trials 
using this methodology, although towards the upper 
end.17 The second was a 100% increase in relative risk, 
that is, a doubling in cumulative probability of failure, as 
this is an easily interpretable outcome.
If a construct had 500 or more patients still at risk, at 
each time point, we calculated the difference in failure 
between that construct and the reference construct. 
Results are graphically reported for all comparator pros-
thesis constructs meeting this criterion at each time point 
of interest. These figures show the failure difference for 
each construct against the reference and the number of 
constructs still at risk. The threshold for graphical presen-
tation, 500 procedures, was chosen based on the previous 
work of Sayers et al8 as this would give rise to an individual 
CI width of ~5% (±2.5%), and because it complements 
the number of procedures at risk used by ODEP when 
evaluating devices at 10 years. However, as this decision 
is somewhat arbitrary, we also present results in a tabular 
format for all comparator prosthesis constructs with at 
least 250 patients at risk at the beginning of the time 
point of interest (see online supplementary tables).
Prosthesis constructs were either classified as non-infe-
rior, inconclusive or inferior. If the upper CI limit is less 
than or equal to the 20% non-inferiority margin, the pros-
thesis construct was non-inferior. If the lower CI of the 
difference was greater than the non-inferiority margin at 
either 20% or 100% the prosthesis construct was classed 
as inferior at 20% or 100%, respectively. If the lower confi-
dence limit is less than the non-inferiority margin, and 
the upper confidence limit greater than non-inferiority 
margin the construct was described as inconclusive, see 
figure 1 for graphical representation of the classification.
sensitivity analysis
We repeated all analyses using a historic reference group, 
this specified the reference at 3, 5 and 7 years as the best 
performing stem–cup prosthesis construct at 10 years 
with at least 1000 still at risk in the stratum of interest.
All analyses were carried out using Stata V.14.2.
results
There were 890 681 primary hip replacements included 
in the NJR between 1 April 2003 and 31 December 
2016. Following the application of the exclusion criteria 
defined above, 797 178 procedures were included in the 
final analysis, see online supplementary figure 1. In total, 
4442 different prosthesis constructs were used at least 
once. A detailed description of non-inferiority across all 
procedures is provided. Due to the large number of clin-
ically relevant subdivisions and sensitivity analyses, results 
will be described more broadly. Constructs are described 
using bearing and brand. Bearings are either ceramic 
(C), metal (M) or polyethylene (P). Brands are described 
listing the stem and cup combination (stem/cup).
Figures were produced for each stratification of gender, 
age group and time since primary. To view data at 3 years 
postprimary for all men, men aged <55 years, men aged 
55–75 years and men aged >75 years, see online supple-
mentary figures 2a–d, respectively. To view data at 5 years 
postprimary for all men, men aged <55 years, men aged 
55–75 years and men aged >75 years, see online supple-
mentary figures 3a–d, respectively. To view data at 7 years 
postprimary for all men, men aged 55–75 years and men 
aged >75 years, see online supplementary figures 4a–c, 
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respectively. To view data at 10 years postprimary for all 
men and men aged 55–75 years, see online supplemen-
tary figures 5a and b, respectively. To view data at 3 years 
postprimary for all women, women aged <55 years, women 
aged 55–75 years and women aged >75 years, see online 
supplementary figures 6a–d, respectively. To view data at 
5 years postprimary for all women, women aged <55 years, 
women aged 55–75 years and women aged >75 years, see 
online supplementary figures 7a–d, respectively. To view 
data at 7 years postprimary for all women, women aged 
<55 years, women aged 55–75 years and women aged >75 
years, see online supplementary figures 8a–d, respec-
tively. To view data at 10 years postprimary for all women 
and women aged 55–75 years, see online supplementary 
figures 9a and b, respectively
Estimates for the difference in failure between 
the reference and comparator prosthesis constructs 
with ≥250 procedure at risk at the time of interest for 
all, and for each stratification of gender and age group 
were tabulated. To view data for all at 3, 5, 7 and 10 
years postprimary, see online supplementary tables 
1a–d, respectively. To view data in all women at 3, 5, 7 and 
10 years postprimary, see online supplementary tables 
2a–d, respectively. To view data for women aged <55 years 
at 3, 5 and 7 years postprimary, see online supplementary 
tables 3a–c, respectively. To view data for women between 
55 and 75 years at 3, 5, 7 and 10 years postprimary, see 
online supplementary tables 4a–d, respectively. To view 
data for women aged >75 years at 3, 5 and 7 years postpri-
mary, see online supplementary tables 5a–c, respectively. 
To view data in all men at 3, 5, 7 and 10 years postprimary, 
see online supplementary tables 6a–d, respectively. To 
view data in men aged <55 years at 3 and 5 years postpri-
mary, see online supplementary tables 7a and b, respec-
tively. To view data in men between 55 and 75 years at 3, 
5, 7 and 10 years postprimary, see online supplementary 
tables 8a–d, respectively. To view data in men aged >75 
years at 3, 5 and 7 years postprimary, see online supple-
mentary tables 9a–c, respectively. In this analysis, there 
were 415 608 implants at risk at 3 years (in constructs with 
at least 500 procedures) and 41 908 at 10 years. Of these, 
there were 3733 implant failures at 3 years and 1325 at 
10 years. The total number of implants at risk and total 
implant failures for each subdivision and time point 
can be seen in online supplementary tables 10a and b, 
respectively.
non-inferiority: all procedures
The reference prosthesis construct at 3 years was identi-
fied as the CoP MS-30/Low profile Muller. There were 
1554 procedures remaining at risk and the failure rate 
was 0.39% (95% CI 0.19 to 0.82). There were 134 pros-
thesis combinations with ≥500 procedures at risk. Ninety 
combinations were classified as inferior to the reference 
by at least 20% relative risk of failure. Forty-four of the 90 
were shown to be inferior by at least 100% relative risk 
(figure 2). No prosthesis constructs could be described 
as non-inferior.
The reference prosthesis construct at 5 years was again 
identified as CoP MS-30/Low profile Muller. There were 
1125 procedures remaining at risk and the failure rate 
was 0.55% (95% CI 0.29 to 1.08). There were 99 pros-
thesis constructs with ≥500 procedures at risk. Seven-
ty-four prosthesis constructs were classified as inferior 
Figure 1 Schematic representation of inferiority and non-inferiority.
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Figure 2 Difference in failure of implanted constructs compared with a contemporary reference at 3 years, using all stem–cup 
combinations with ≥500 procedures remaining at risk. CoC, ceramic-on-ceramic; CoP, ceramic-on-polyethylene; MoP, metal-
on-polyethylene. 
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to the reference by at least 20% relative risk of failure. 
Thirty-nine of the 74 were shown to be inferior by at least 
100% relative risk (figure 3). No prosthesis constructs 
could be described as non-inferior.
The reference prosthesis constructs at 7 years was iden-
tified as the MoP Exeter V40/Elite Plus Cemented Cup. 
There were 1173 procedures remaining at risk and the 
failure rate was 0.91% (95% CI 0.64 to 1.28). There were 
69 prosthesis constructs with ≥500 procedures at risk. 
Forty-eight prosthesis constructs were classified as infe-
rior to the reference by at least 20% relative risk of failure. 
Twenty of the 48 were shown to be inferior by at least 
100% relative risk (figure 4). No prosthesis constructs 
could be described as non-inferior.
The reference prosthesis constructs at 10 years was 
identified as the MoP Exeter V40/Elite Plus Ogee. There 
were 3580 procedures remaining at risk and the failure 
rate was 2.14% (95% CI 1.87 to 2.45). There were 26 
prosthesis constructs with ≥500 procedures at risk. Twelve 
prosthesis constructs were classified as inferior to the 
reference by at least 20% relative risk of failure. One of 
the 12 was shown to be inferior by at least 100% relative 
risk (figure 5). Two prosthesis constructs were identified 
as non-inferior.
non-inferiority: gender specific
Gender-specific non-inferiority analyses were also 
performed at 3, 5, 7 and 10 years after the primary 
operation.
At 3 years, only a small number of prosthesis constructs 
demonstrated non-inferiority in comparison to the refer-
ence. Most striking is the large variability of prosthesis 
constructs used in females compared with males (58 
different prosthesis constructs were used >500 times in 
males vs 93 in females), and the gender-specific heteroge-
neity in performance. For example, the CoP Exeter V40/
Exeter Contemporary Flanged is used as the reference at 
3 years in males, yet is inferior by 20% compared with 
the reference in females at 3 years. A performance differ-
ence was also noted in the CoC SL-Plus cementless Stem/
EP-Fit Plus between the genders. At 3 years, the failure 
rate for this prosthesis constructs in all females was 1.75% 
yet in males after the same period the failure was 5.11% 
(p<0.001).
At 5 years, the reference failure rate in females is less 
than half that in males. While there are only 3 prosthesis 
constructs marked as 100% worse than the reference pros-
thesis construct in males, there are 24 prosthesis constructs 
that are 100% worse than the reference in females. Some 
prosthesis constructs have been used in large numbers 
despite having relatively poor performance.
At 7 years, the reference failure rate in females remained 
less than half that of males. There were no prosthesis 
constructs, used in sufficient numbers, which could be 
described as non-inferior to the reference in both males 
and females. One prosthesis construct in males was at 
least 100% worse than the reference, while 14 prosthesis 
constructs were at least 100% worse in females.
At 10 years, no prosthesis constructs were described as 
non-inferior to the reference in both males and females 
and there were no implants inferior by 100% in either 
males or females.
non-inferiority: gender and age specific
Subdividing procedures by age and gender highlights the 
paucity of information available pertaining to either male 
or female patients <55 years undergoing THR. Similarly, 
the volume of longer-term outcomes on patients beyond 
7 years is relatively low in comparison to the number of 
implanted prosthesis constructs. Most strikingly is the 
preference for hard-on-hard bearing surfaces (such as 
CoC) in younger male patients (<55 years). Five of the 
six prosthesis constructs with at least 500 procedures at 3 
years were CoC, contrasted with the vast majority of pros-
thesis constructs used in older male patients (≥55 years) 
where either MoP or CoP bearing couples were used. In 
addition, changes to the distribution of failure rates of 
prostheses become increasingly apparent. For example, 
the reference prosthesis construct in men aged <55 years 
at 3 years has a cumulative failure of 1.26%, whereas the 
failure rate of the reference in men aged over 75 years at 
3 years has a cumulative failure of 0.78%. This is a 60% 
increase in relative failure rate of the reference proce-
dure for younger males compared with the reference 
procedure for older males.
The paucity of constructs in each age/gender group 
which have been utilised over 500 times and for which 
non-inferiority to the reference prosthesis construct is 
demonstrated is notable. For men aged <55 years, only 
four prosthesis constructs (including the reference 
construct) meet this requirement at 3 years, three pros-
thesis constructs at 5 years and none thereafter. For 
women of the same age, the numbers are 4 at 3 years, 3 
at 5 years and 7 at 7 years, with none at 10 years. In the 
largest grouping, those aged between 55 and 75 years, for 
men, 16 prosthesis constructs meet this requirement at 5 
years and only 7 at 10 years, while for women the numbers 
are 12 at 5 years and 9 at 10 years.
sensitivity analysis
We conducted a sensitivity analysis which used the refer-
ence prosthesis construct at 10 years as the reference at 
3, 5 and 7 years. We assume that the failure trajectory of a 
non-inferior construct will have the same or lower failure 
rate compared with the reference construct at 3, 5, 7 and 
10 years. This approach is conservative, as it preserves the 
status quo with respects implant performance. The refer-
ence construct in all procedures at 10 years is the Exeter 
V40/Elite Plus Ogee with a failure rate of 2.14% (95% CI 
1.87 to 2.45). Only one prosthesis construct is non-infe-
rior and statistically superior, that is, the Exeter V40/Elite 
Plus Cemented cup, but it does not have 1000 implants at 
risk at 10 years and therefore is not considered to be the 
reference construct. At 7, 5 and 3 years, the contemporary 
reference has a 0.59%, a 0.55% and 0.40% lower failure 
rate than the historical reference, respectively. While the 
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Figure 3 Difference in failure of implanted constructs compared with a contemporary reference at 5 years, using all stem–cup 
combinations with ≥500 procedures remaining at risk. CoC, ceramic-on-ceramic ; CoP, ceramic-on-polyethylene; MoP, metal-
on-polyethylene. 
 o
n
 7 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026685 on 29 April 2019. Downloaded from 
8 Deere KC, et al. BMJ Open 2019;9:e026685. doi:10.1136/bmjopen-2018-026685
Open access 
good performance of many prosthesis constructs appear 
to track, some exhibit substantially variability in their rela-
tive performance at the times of interest. Specifically, the 
MoP Exeter V40/Charnley Ogee is non-inferior to the 
historical reference at 10 years, but is inferior by 20% at 
5 years.
DIsCussIOn
We have demonstrated in 797 178 primary THRs the rela-
tive performance of implanted prosthesis constructs in 
comparison to an internally selected contemporary refer-
ence. There is substantial variation in the performance 
of prosthesis constructs. A non-inferiority approach 
to benchmarking provides an immediate comparison 
of commonly used implanted prosthesis constructs 
compared with an internal contemporary reference 
and conveys distinct advantages opposed to standard 
Kaplan-Meier analyses as currently reported in the NJR 
annual reports or categorical grades provided by ODEP. 
The heterogeneity in implanted constructs in females 
Figure 4 Difference in failure of implanted constructs compared with a contemporary reference at 7 years, using all stem–cup 
combinations with ≥500 procedures remaining at risk. CoC, ceramic-on-ceramic ; CoP, ceramic-on-polyethylene; MoP, metal-
on-polyethylene. 
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compared with males is aptly illustrated, as is the paucity 
of information in clinically relevant substrata. The marked 
differences in outcomes between the different age/
gender substrata confirm the importance of comparing 
prosthesis constructs within these strata.13 We present this 
study as a novel way of assessing hip prosthesis constructs 
and as such there is, in the authors opinion, no relevant 
evidence published to date.
What is most striking is that so few prosthesis constructs 
in each age/gender strata meet the criteria of 500 cases 
at each time point and are at least classified as ‘inferiority 
not shown’. Of the 4442 constructs used, only seven meet 
these criteria in men aged 55–75 years (online supple-
mentary figure 5b) and nine in women aged 55–75 years 
at 10 years (online supplementary figure 9b). None meet 
the criteria in any other age/gender substrata at 10 years. 
Even at the relatively short follow-up of 5 years, only 16 
constructs in men (online supplementary figure 3c) 
and 12 in women aged 55–75 years (online supplemen-
tary figure 7c) meet these criteria. Patients would have 
a reasonable expectation that the implants they receive 
have a proven track record and have not been demon-
strated as having a 20% or more increased revision rate 
for patients of the same age and gender. It is important 
to note that some prosthesis constructs have a higher 
early relative failure rate and a lower relative failure rate 
in later years and thus are inferior at 3, 5 and 7 years, 
but inferiority is not shown at 10 years. Examples of this 
in men aged 55–75 years are the MoP Corail/Pinnacle 
and MoP Exeter/Contemporary hooded, we believe this 
effect is principally driven by the lower failure of the refer-
ence at earlier timepoints, that is, a reduction in revision 
rate with a later cohort. Late failure is preferential to early 
failure from the patient, societal and health economic 
perspectives, particularly as early revision is unfortunately 
associated with a high rate of rerevision.18
One of the most obvious trends across all stratifications 
is the outstanding performance of the Exeter V40 stem as 
part of various prosthesis constructs. However, the hetero-
geneity in acetabular prostheses paired with the Exeter 
V40 stem is substantial, as is the subsequent variation in 
performance. This aptly illustrates the need to bench-
mark constructs opposed to individual implants which 
make up prosthesis constructs, which has the potential 
to provide false reassurance in terms of efficacy as the 
individual elements of a construct are not independent. 
Patient-specific construct selection is another strong 
feature of the data, with the majority of younger patient 
receiving CoC bearing surfaces, whereas the majority of 
older patients receive MoP bearing surfaces.
This analysis does show that certain constructs are 
either the reference or are non-inferior to the refer-
ence prosthesis construct across almost all age and 
gender strata. This strongly suggests that they could 
Figure 5 Difference in failure of implanted constructs compared with a contemporary reference at 10 years, using all stem–cup 
combinations with ≥500 procedures remaining at risk. CoC, ceramic-on-ceramic ; CoP, ceramic-on-polyethylene; MoP, metal-
on-polyethylene. 
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appropriately be used as default options for the majority 
of patients. This is particularly relevant for inexperienced 
surgical teams, as they can focus training on, and become 
expert with, a single prosthesis construct. This has the 
potential to reduce the risk of technical error, to be cost 
saving through bulk purchasing arrangements and via a 
reduction in failure rates. The absolute level of failure 
of commonly used constructs is relatively low, and <5% 
in many instances. This apparently excellent (ODEP 
10A*) performance is exhibited by nearly all prosthesis 
constructs with sufficient data at 10 years (≥500 patients 
at risk) and raises questions about whether an externally 
placed benchmark is the optimal way to ensure best care.
Encouragingly, the sensitivity analysis demonstrates the 
prognosis for patients undergoing hip replacement is 
continually improving, and the currently best performing 
implant at 10 years is unlikely to be as good as the contem-
porary references at 3, 5 and 7 years when these reach 10 
years of follow-up. While the refinement of clinical prac-
tice and development of prosthesis constructs appears to 
be raising the bar in performance, it is clear that these 
improvements are not universal. This raises questions 
about how implants are introduced into a market safely; 
ensuring enough prosthesis constructs are implanted 
to ascertain their relative performance, but no more 
than the necessary number of prosthesis constructs are 
implanted to minimise the exposure of patients to poor 
performing implants, and finally to ensure there is suffi-
cient incentive for implant manufacturers to develop new 
prostheses that benefit patients.
This analysis has a number of important strengths. We 
explicitly compare prosthesis constructs to a contem-
porary reference, and a historical defined reference 
with known performance using a non-inferiority study 
design. The unambiguous presentation of data allows 
surgeons, patients and policy makers to directly compare 
commonly used prosthesis constructs to a reference 
construct. We illustrate the paucity of information in clin-
ically relevant substrata and the need to compare implant 
constructs opposed to implant elements. The analysis has 
a number of limitations; case-mix adjustment by strat-
ification is difficult to assimilate despite the restricted 
set of confounding factors. Residual and unmeasured 
confounding factors are likely to be present, and the 
ability to interpret analyses from a causal perspective is 
limited. It is also known that revision rate is influenced 
by factors such as the primary indication. In this study, 
there is a breadth of indications for the primary proce-
dure; however, 89.1% (709 902) of procedures had osteo-
arthritis listed as the only reason for primary whereas 
fractured neck of femur was the reason for primary in 
23 336 (2.9%) cases. The NJR annual report illustrates 
that neck of femur fracture is associated with a small 
increase in risk of revision in the first 6 months, but then 
revision rate is approximately equal to other patients.3 
The number of patients remaining at risk after extended 
follow-up is low, and therefore the power to detect non-in-
feriority assuming there is truly no difference in prosthesis 
constructs compared with the reference is also low. This 
phenomenon is further compounded when we compare 
stratum-specific performance of constructs at nearly all 
time points. Whilst reducing the number of procedures 
required to be at risk may be appealing, to increase the 
number of comparisons, the precision of those compari-
sons would be low, and therefore not informative. It is also 
possible that the constructs listed in this analysis may use 
a mixture of liner materials (ie, cross-linked polyethylene 
[XLPE] and non-XLPE) which may lead to variation of 
revision rates within constructs. Data entry is mandated 
and data capture is extremely high (over 95%),15 thus 
the findings in this study are highly likely to be generalis-
able. Furthermore, the reasons for failing to record those 
remaining primaries or revisions in the NJR is unlikely to 
related to the choice of implant. Therefore, these data 
would be classified as missing completely at random and 
would be unlikely to bias our results.19
Conclusions, policy and future research implications
The use of product benchmarking has the potential to 
be highly informative for patients, change the practice 
of surgeons and influence policy makers if presented 
clearly and unambiguously. Clinical implications of this 
research are far reaching. We are unable to definitively 
state which construct is the best choice for all patients, 
due to the presence of selection effects and residual 
confounding. However, we believe that the information 
presented here illustrates the variability, frequency and 
performance of different constructs currently used in 
clinical practice. This in turn, should be used to further 
inform the consenting process between the patient and 
the surgeon, and facilitate implant selection. We believe 
commissioners and policy makers should consider the 
variability and performance of different implants before 
commissioning healthcare providers. Furthermore, qual-
itative research is required to understand why surgeons 
select new implants, with limited understanding of long-
term performance, in favour of constructs with demon-
strably low failure rates, for example, the (MoP) Exeter 
V40 Elite plus Ogee, (MoP) Exeter V40 Charnley Ogee, 
(MoP) Exeter V40 Elite plus cemented cup which repre-
sented only ~1% of the 91 698 constructs implanted in the 
NJR in 2017.3
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